Background: Allergen immunotherapy (AIT) is the unique causal treatment for respiratory allergy. As AIT is expensive and of long duration, the availability of a marker predicting AIT responders is of crucial relevance. Objective: To investigate clinical parameters correlated with effective AIT in allergic rhinitis (AR) patients. Methods: This is a prospective, nonrandomized open study in which a total of 284 AR patients who had received house dust mite (HDM) subcutaneous AIT were enrolled from January 2011 to December 2015, and then followed up for 3 consecutive years. Demographic data, clinical history, laboratory tests (specific and total IgE levels), symptoms score, concomitant medication, and adverse reactions during AIT were collected. An AIT responder patient was defined when a visual analog score (assessing global symptoms) had decreased by >30% compared to baseline and concomitant medication was equal to or less than before AIT. Results: Thirty-three patients dropped out, so 251 patients were analyzed; 175 (69.7%) patients were responders. This group had a higher baseline symptom score than the AIT nonresponder group (7.5 vs. 6.9). A significant negative correlation was found between AR symptom duration and the clinical response to AIT. Local reactions (LRs) during AIT had a positive correlation. Other variables such as a family history of atopy, combined asthma history, and the levels of specific and total IgE had no correlations with effective AIT. Conclusion: Early intervention with AIT helps to improve the efficacy of AR treatment. LRs might predict successful AIT. Highly symptomatic AR patients may develop increased clinical responses to AIT.

Long A, McFadden C, DeVine D, Chew P, Kupelnick B, Lau J: Management of allergic and nonallergic rhinitis. Evid Rep Technol Assess 2002;54:1-6.
Zhang L, Han D, Huang D, Wu Y, Dong Z, Xu G, Kong W, Bachert C: Prevalence of self-reported allergic rhinitis in eleven major cities in China. Int Arch Allergy Immunol 2009;149:47-57.
Malling HJ, Bousquet J: Subcutaneous immunotherapy for allergic rhinoconjunctivitis, allergic asthma, and prevention of allergic diseases. Clin Allergy Immunol 2008;21:343-358.
Wilson DR, Lima MT, Durham SR: Subligual immunotherapy for allergic rhinitis: systemic review and meta-analysis. Allergy 2005;60:4-12.
Price D, Smith P, Hellings P, et al: Current controversies and challenges in allergic rhinitis management. Expert Rev Clin Immunol 2015;11:1205-1217.
Li Q, Li M, Yue W, Zhou J, Li R, Lin J, Li Y: Predictive factors for clinical response to allergy immunotherapy in children with asthma and rhinitis. Int Arch Allergy Immunol 2014;164:210-217.
Di Lorenzo G, Mansueto P, Pacor ML, Rizzo M, Castello F, Martinelli N, Ditta V, Lo Bianco C, Leto-Barone MS, D'Alcamo A, Di Fede G, Rini GB, Ditto AM: Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy. J Allergy Clin Immunol 2009;123:1103-1110.
Ciprandi G, Silvestri M: Serum specific IgE: a biomarker of response to allergen immunotherapy. J Investig Allergol Clin Immunol 2014;24:35-39.
Fujimura T, Yonekura S, Horiguchi S, Taniguchi Y, Saito A, Yasueda H, Inamine A, Nakayama T, Takemori T, Taniguchi M, Sakaguchi M, Okamoto Y: Increase of regulatory T cells and the ratio of specific IgE to total IgE are candidates for response monitoring or prognostic biomarkers in 2-year sublingual immunotherapy (SLIT) for Japanese cedar pollinosis. Clin Immunol 2011;139:65-74.
Calderón MA, Linneberg A, Kleine-Tebbe J, De Blay F, Hernandez Fernandez de Rojas D, Virchow JC, Demoly P: Respiratory allergy caused by house dust mites: what do we really know? J Allergy Clin Immunol 2015;136:38-48.
Bousquet J, Khaltaev N, Cruz AA: Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(suppl 86):8-160.
Dong X, Huang N, LI W, Hu L, Wang X, Wang Y, Xiang N, Liu G, Zhu R: Systemic reactions to dust mite subcutaneous immunotherapy: a 3-year follow-up study. Allergy Asthma Immunol Res 2016;8:421-427.
Tabar AI, Arroabarren E, Echechipia S, Garcia BE, Martin S, Alvarez-Puebla MJ: Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. J Allergy Clin Immunol 2011;127:57-63.
Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G: Speaking the same language: the World Allergy Organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol 2010;125:569-574.
Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, Cox L, Demoly P, Frew AJ, O'Hehir R, Kleine-Tebbe J, Muraro A, Lack G, Larenas D, Levin M, Nelson H, Pawankar R, Pfaar O, van Ree R, Sampson H, Santos AF, Du Toit G, Werfel T, Gerth van Wijk R, Zhang L, Akdis CA: International consensus on allergy immunotherapy. J Allergy Clin Immunol 2015;136:556-568.
Ciprandi G, Tosca MA, Silvestri M: The practical role of serum allergen-specific IgE as potential biomarker for predicting responder to allergen immunotherapy. Expert Rev Clin Immunol 2014;10:321-324.
Alvarez Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E: Standards for practical allergen-specific immunotherapy. Allergy 2006;61(suppl 82):1-20.
Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M, Bonini S, Bousquet J, Calderón M, Compalati E, Durham SR, van Wijk RG, Larenas-Linnemann D, Nelson H, Passalacqua G, Pfaar O, Rosário N, Ryan D, Rosenwasser L, Schmid-Grendelmeier P, Senna G, Valovirta E, Van Bever H, Vichyanond P, Wahn U, Yusuf O: Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J 2014;7:6.
Park SJ, Jun YJ, Kim TH, Jung JY, Hwang GH, Jung KJ, Lee SH, Lee HM, Lee SH: Increased expression of YKL-40 in mild and moderate/severe persistent allergic rhinitis and its possible contribution to remodeling of nasal mucosa. Am J Rhino Allergy 2013;27:372-380.
Eifan AO, Orban NT, Jacobson MR, Durham SR: Severe persistent allergic rhinitis. Inflammation but no histologic features of structural upper airway remodeling. Am J Respir Crit Care Med 2015;192:1431-1439.
Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, Nelson M, Weber R, Bernstein DI, Blessing-Moore J, Khan DA, Lang DM, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph C, Schuller DE, Spector SL, Tilles S, Wallace D: Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011;127(1 suppl):S1-S55.
Moreno V, Alvariño M, Rodríguez F, Roger A, Peña-Arellano MI, Lleonart R, Pagán JA, Navarro JA, Navarro LA, Vidal C, Ponte-Tellechea A, Gómez-Fernández MC, Madariaga-Goirigolzarri B, Asturias JA, Hernández-Fernandezde Rojas D: Randomized dose-response study of subcutaneous immunotherapy with a Dermatophagoides pteronyssinus extract in patients with respiratory allergy. Immunotherapy 2016;8:265-277.
Howarth P, Malling HJ, Molimard M, Devillier P: Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients. Allergy 2012;67:321-327.
Amini P, Abdullah M, Seng LS, Karunakaran T, Hani N, Bakar SA, Latiff AH, Fong SH, Yeow YY: Ethnicity influences disease characteristics and symptom severity in allergic rhinitis patients in Malaysia. Int Forum Allergy Rhino 2016;6:624-630.
Tosca M, Silvestri M, Accogli A, Rossi GA, Ciprandi G: Serum-specific IgE and allergen immunotherapy in allergic children. Immunotherapy 2014;6:29-33.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.